Health score, price, valuation, risk signals, and key metrics at a glance.
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa, Latin America, Asia, and the United States. The company offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides breast tissue expanders. The company sells products to physicians, hospitals, and clinics through distributors and its direct sales force. Establishment Labs Holdings Inc. was incorporated in 2004 and is based in Austin, Texas.
Strongest: Growth (20/25); weakest: Balance Sheet & Red Flags (6/25).
Today's multiple positioned against its own trailing range — a visual premium/discount check.
Currently near its 20-quarter median.
Currently above its 18-quarter median.
Data-driven signals worth keeping an eye on across the last 8 quarters
The company posted negative operating margins in recent quarters — core operations are unprofitable.
Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.
as of June 2026
Revenue, EBITDA, operating income, net income, EPS, and shares
Gross, EBITDA, operating, and net margin trends
P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield
Total assets, cash, debt, book value, and leverage
Operating cash flow, free cash flow, FCF margin, and earnings quality
D/E ratio is 12.1 — heavily leveraged and vulnerable to rising rates or cash flow dips.
The last 8 consecutive quarters had negative FCF — the company is burning cash and may need external funding.
Shares outstanding increased 6.6% — significant dilution, likely from stock compensation or capital raises.
